| Code | CSB-RA021334MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to BSI-082, targeting signal regulatory protein alpha (SIRPα), a critical immune checkpoint receptor expressed primarily on myeloid cells including macrophages and dendritic cells. SIRPα interacts with CD47, a "don't eat me" signal widely expressed on normal cells, to inhibit phagocytosis and regulate innate immune responses. This pathway plays a pivotal role in immune homeostasis and self-tolerance. Dysregulation of the SIRPα-CD47 axis has been implicated in various cancers, where tumor cells exploit CD47 overexpression to evade macrophage-mediated destruction, as well as in inflammatory and autoimmune conditions.
BSI-082 represents a therapeutic antibody approach to modulate the SIRPα-CD47 interaction, with potential applications in immuno-oncology research. This biosimilar antibody serves as a valuable research tool for investigating SIRPα biology, studying macrophage function, exploring innate immune checkpoint mechanisms, and evaluating therapeutic strategies targeting the CD47-SIRPα pathway in cancer and immune-related disease models. It enables researchers to advance understanding of myeloid cell regulation and tumor immunology.
There are currently no reviews for this product.